Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The company develops precision medicine treatments for unmet medical needs, with a primary focus on oncology and hematology. Its lead candidate, ELVN-001, is a potent, highly selective small molecule kinase inhibitor targeting the BCR-ABL gene fusion in chronic myeloid leukemia (CML). ELVN-001 is currently being evaluated in the Phase 1 ENABLE clinical trial and is planned for a Phase 3 pivotal trial in 2026. The company also advanced ELVN-002, a central nervous system penetrant and irreversible HER2 inhibitor, though it has since prioritized ELVN-001. Enliven’s pipeline includes research-stage opportunities in diseases such as Graves’ disease, utilizing a target- and indication-agnostic approach to address acquired resistance and improve therapeutic profiles.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage enliventherapeutics.com
Sector Healthcare IR page ir.enliventherapeutics.com
Tags
small molecule therapeutics, kinase inhibitors, chronic myeloid leukemia, bcr-abl, her2, precision medicine, oncology, hematology, graves' disease, ELVN-001, ELVN-002, ENABLE, ENABLE-2
Press page —

Metrics

Valuation  
Market cap $ 2.83B
Market cap (USD) $ 2.83B
P/E -22.90
PEG —
P/BV 3.23
P/S —
P/OCF -42.74
P/FCF -42.62
Dividend yield —
Turnover / mcap —
Returns  
ROE -27.0%
ROI -28.7%
ROIC -24.9%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 31
Quality score -83.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Assets 476.168M 325.76M 271.867M 91.959M 93.646M 90.842M 33.298M
Net profit -103.694M -89.024M -71.584M 1.488M -51.384M -41.36M -23.463M
Free cash flow -70.459M -73.236M -61.418M -35.931M -46.783M -37.416M -22.017M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 15.4 22.5 13.84 — — — —
Price performance 12m -0.32 0.63 — — — — —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — — 652,000 — 335,000 — 399,000
Cash and deposits (USD) 7.38M 4.94M 47.7M 48.3M 88.2M 100M 124M 98.9M
Right-of-use assets (USD) — — — 525,000 626,000 320,000 0.00 383,000
Cash flow detail
Operating cash flow (USD) — -21.9M -37.4M -46.8M -35.6M -61.3M -73.2M -70.3M
Purchases of property, plant and equipment (USD) — -140,000 -18,000 -12,000 -363,000 -149,000 -44,000 -158,000
Change in payables (cash effect) (USD) — 750,000 313,000 389,000 -2.21M -2.25M 810,000 817,000
Income taxes paid (cash effect) (USD) — — — — — 0.00 -232,000 0.00
Share-based compensation (USD) — 899,000 2.23M 3.85M 2.6M 12.9M 20.2M 34M
Free cash flow (OCF - PPE - intangibles) (USD) — -22M -37.4M -46.8M -35.9M -61.4M -73.2M -70.5M
Income detail
Research and development expense (USD) — 19M 32.2M 38.4M 18.9M 64.6M 80.8M 85.9M
↳ 5y CAGR +33.6% +21.7%
Total comprehensive income (USD) — -23.4M -41.4M -51.4M 1.5M -71.4M -89.1M -103M
Comprehensive income to owners (USD) — -23.4M -41.4M -51.4M 1.5M -71.4M -89.1M -103M
Reported May 7, 2020 Mar 5, 2021 Mar 5, 2021 Mar 15, 2022 May 11, 2023 Mar 13, 2025 Mar 13, 2025 Mar 3, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 5, 2026

PDF Version

Reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial

On track to initiate ENABLE-2 before year-end 2026

Strong balance sheet with $884 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into 2030

BURLINGAME, Calif., Nov. 5, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.

"This quarter marked an important milestone for Enliven as we reached alignment with the FDA on the final design of ENABLE-2, providing a clear path to initiate our first pivotal trial," said Rick Fair, Chief Executive Officer of Enliven. "The compelling ENABLE data presented at EHA in June generated strong engagement across the medical community, and we are encouraged by the enthusiasm from physicians and investigators as we prepare to initiate ENABLE-2. As we approach year-end, we remain confident in relcobatinib's potential to become a best-in-class therapy for patients with CML and are focused on executing our Phase 3 development program."

Relcobatinib Updates

  • The United States Adopted Names (USAN) Council adopted relcobatinib as the nonproprietary name for ELVN-001.

  • The Company announced that it reached alignment with the U.S. Food and Drug Administration (FDA) on the final design of the ENABLE-2 pivotal trial of relcobatinib in patients with previously treated chronic myeloid leukemia (CML).

  • Clinical data for relcobatinib from the Phase 1 ENABLE trial were featured in encore oral presentations at the meetings of the Society of Hematologic Oncology (SOHO), the International CML Foundation (ESH-iCMLf), the Japanese Society of Hematology (JSH) and the German Society for Hematology and Medical Oncology (DGHO), reflecting continued enthusiasm for its clinical profile.

  • Preclinical data published in the peer-reviewed journal Leukemia demonstrated relcobatinib's unique binding mode, high selectivity for BCR::ABL1 and activity against a broad range of clinically relevant tyrosine kinase inhibitor (TKI)-resistant mutations, supporting its potential as a best-in-class TKI for CML.

  • The Company remains on track to initiate ENABLE-2 before year-end 2026.

Additional Company Updates

  • Enliven appointed Kristine Ball, an accomplished biopharmaceutical executive, to its Board of Directors.

  • Management will participate at the following investor conferences:

  • Guggenheim Healthcare Innovation Conference, November 9-11, Boston, MA (Fireside Chat and 1x1 Meetings)

  • Stifel Healthcare Conference, November 10-12, New York, NY (1x1 Meetings)

  • Jefferies Global Healthcare Conference, November 16-19, London, UK (Fireside Chat and 1x1 Meetings)

  • The fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website at https://ir.enliventherapeutics.com/. The webcast will be archived for a period of 90 days following the conclusion of the live event.

Third Quarter 2026 Financial Results

  • Cash position: As of September 30, 2026, the Company had cash, cash equivalents and marketable securities totaling $884.4 million, which is expected to provide cash runway into 2030.

  • Research and development (R&D) expenses: R&D expenses were $28.0 million for the third quarter of 2026, compared to $18.2 million for the third quarter of 2025.

  • General and administrative (G&A) expenses: G&A expenses were $8.0 million for the third quarter of 2026, compared to $6.9 million for the third quarter of 2025.

  • Net loss: Enliven reported a net loss of $27.7 million for the third quarter of 2026, compared to a net loss of $20.1 million for the third quarter of 2025.

About Relcobatinib (ELVN-001) Relcobatinib (ELVN-001) is a potent, highly selective, potentially best-in-class small molecule kinase inhibitor designed to specifically target the BCR::ABL1 gene fusion, the oncogenic driver for patients living with CML. As a highly selective active-site TKI, relcobatinib has a mechanism of action that is complementary to allosteric BCR::ABL1 inhibitors, which may play an increasingly important role in the standard of care. Relcobatinib was also designed to have activity against the T315I mutation, the most common BCR::ABL1 mutation, which confers resistance to nearly all approved TKIs, as well as activity against mutations known to confer resistance to allosteric BCR::ABL1 inhibitors.

About the ENABLE-2 Trial ENABLE-2 is a planned randomized Phase 3 trial of relcobatinib in adults with CML previously treated with one or more TKIs. The trial is expected to enroll approximately 450 patients, who will be randomized 1:1 to receive relcobatinib 80 mg once daily or an investigator-selected second-generation TKI (dasatinib, nilotinib, or bosutinib). The primary endpoint is major molecular response (MMR) at Week 24, which could support accelerated approval, with MMR at Week 96 serving as the key secondary endpoint that could support full approval.

About Enliven Therapeutics Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision medicine approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights into clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Burlingame, California. To learn more, visit www.enliventherapeutics.com and connect with us on LinkedIn and X.

Forward-Looking StatementsThis press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning Enliven and other matters that involve substantial risks and uncertainties. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations and financial condition, or otherwise, based on current beliefs of Enliven's management, as well as assumptions made by, and information currently available to, Enliven's management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Statements that are not historical facts are forward-looking statements. Forward-looking statements in this press release include, but are not limited to: statements regarding the potential profile, activity, selectivity, safety, tolerability, efficacy, differentiated attributes, therapeutic benefit and potential best-in-class profile of relcobatinib; the interpretation of data from the ongoing ENABLE trial, including MMR rate, safety and tolerability data; the timing, content and availability of additional clinical data and presentation materials; the continued conduct, design, objectives, endpoints, dose selection and future clinical evaluation of relcobatinib, including the planned ENABLE-2 Phase 3 trial, the potential timing of initiation of ENABLE-2, the potential timing and outcome of the Phase 3 trial; Enliven's expected cash runway; and statements by Enliven's Chief Executive Officer. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various risks and uncertainties, including, without limitation: the potential for interim, topline and preliminary results from Enliven's clinical trials to materially change as additional patient data become available or following more comprehensive review; the potential for results from the ongoing or any future clinical trial of relcobatinib to differ from the results of earlier trials of relcobatinib; relcobatinib failing to demonstrate sufficient safety, efficacy, tolerability, durability, differentiated attributes or therapeutic benefit in current or future clinical trials; risks associated with unexpected events during the remainder of the ENABLE trial including serious adverse events, toxicities, dose reductions, discontinuations or other undesirable side effects; delays or difficulties in recruiting, enrolling or maintaining patients in relcobatinib clinical trials; the risks of delays in completing the ongoing ENABLE trial or initiating ENABLE-2; Enliven failing to complete the ongoing ENABLE trial, to present additional data, to initiate ENABLE-2 or to advance relcobatinib through clinical development; regulatory authorities disagreeing with Enliven's clinical trial design, dose selection, endpoints or interpretation of data, or requiring additional studies or diagnostics; developments relating to Enliven's competitors and industry which may affect the development or potential market opportunity for relcobatinib; the potential inability of Enliven to obtain regulatory approval for, or ultimately commercialize or license, relcobatinib or other product candidates; Enliven's limited resources; the ability to attract, hire, and retain highly skilled executive officers and employees; the ability of Enliven to protect its intellectual property and proprietary technologies; the scope of any patent protection Enliven obtains or the loss of any of Enliven's patent protection; reliance on third parties, including medical institutions, contract manufacturing organizations, contract research organizations and strategic partners; geopolitical developments, general market or macroeconomic conditions; the risk that Enliven's cash runway estimate is based on assumptions that may prove to be wrong and that Enliven may use its capital resources sooner than it expects; Enliven's ability to obtain additional capital to fund Enliven's general corporate activities and to fund Enliven's research and development; and other risks and uncertainties more fully described in Enliven's filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in Enliven's Annual and Quarterly Reports on Form 10-K and Form 10-Q filed with the SEC and in Enliven's future SEC filings. Except as required by applicable law, Enliven undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.

| Enliven Therapeutics, Inc. |

| Selected Condensed Consolidated Financial Information |

| (in thousands, except per share data) |

| (unaudited) |

| | | | | | | | | | |

| Statements of Operations | | | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | | | 2026 | | 2025 | | 2026 | | 2025 |

| Operating expenses: | | | | | | | | | |

| Research and development | | | $ 28,024 | | $ 18,225 | | $ 77,707 | | $ 64,611 |

| General and administrative | | | 8,021 | | 6,871 | | 23,370 | | 20,762 |

| Total operating expenses | | | 36,045 | | 25,096 | | 101,077 | | 85,373 |

| Loss from operations | | | (36,045) | | (25,096) | | (101,077) | | (85,373) |

| Other income (expense), net | | | 8,342 | | 4,948 | | 17,262 | | 11,346 |

| Net loss | | | $ (27,703) | | $ (20,148) | | $ (83,815) | | $ (74,027) |

| Net loss per share, basic and diluted | | | $ (0.36) | | $ (0.32) | | $ (1.21) | | $ (1.35) |

| Weighted-average shares outstanding, basic and diluted | | | 77,982 | | 62,094 | | 69,040 | | 54,794 |

| | | | | | | | | | |

| Balance Sheets | | | | | September 30, | | December 31, |

| | | | | | 2026 | | 2025 |

| Assets | | | | | | |

| Current assets: | | | | | | |

| Cash, cash equivalents and marketable securities | | | | $ 884,351 | | $ 462,621 |

| Prepaid expenses and other current assets | | | | 10,405 | | 12,257 |

| Total current assets | | | | 894,756 | | 474,878 |

| Property and equipment, net | | | | 201 | | 34 |

| Operating lease right-of-use assets | | | | 1,306 | | 383 |

| Deferred offering costs | | | | — | | 217 |

| Other long-term assets | | | | 962 | | 656 |

| Total assets | | | | $ 897,225 | | $ 476,168 |

| Liabilities and Stockholders' Equity | | | | | | |

| Current liabilities: | | | | | | |

| Accounts payable | | | | $ 2,730 | | $ 2,159 |

| Accrued expenses and other current liabilities | | | | 16,743 | | 14,409 |

| Total current liabilities | | | | 19,473 | | 16,568 |

| Long-term liabilities | | | | 805 | | — |

| Total liabilities | | | | 20,278 | | 16,568 |

| Stockholders' equity | | | | 876,947 | | 459,600 |

| Total liabilities and stockholders' equity | | | | $ 897,225 | | $ 476,168 |

Enliven Logo

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/enliven-therapeutics-reports-third-quarter-2026-financial-results-and-provides-a-business-update-302931099.html

SOURCE Enliven Therapeutics, Inc.

Investors, [email protected], [email protected]

Print Page

Email Alerts

RSS Feeds

Contact Us

October 14, 2026

PDF Version

Accomplished biopharmaceutical executive with extensive experience in corporate strategy, finance and commercial readiness

Enliven continues preparation for late-stage development and commercialization, as it plans to initiate the pivotal Phase 3 trial of relcobatinib before year-end

BURLINGAME, Calif., Oct. 14, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the appointment of Kristine Ball to its Board of Directors, effective immediately. Ms. Ball brings more than 20 years of executive experience across clinical-stage and commercial-stage biopharmaceutical companies.

"We are pleased to welcome Kristine Ball to our Board," said Rick Fair, Chief Executive Officer of Enliven. "Her experience helping companies transition from clinical development to commercial operations will bring valuable perspective as we prepare to initiate our pivotal Phase 3 trial of relcobatinib before year-end and plan for commercialization. We look forward to her contributions as we work to deliver a differentiated treatment option for people living with chronic myeloid leukemia and create long-term value for our shareholders."

"Having seen the impact of CML on a member of my family, I feel a personal connection to Enliven's mission of helping people with CML not only live longer, but live better," said Ms. Ball. "I'm excited to contribute as the Company navigates this transition and prepares for potential commercialization. I look forward to working with the Board and leadership team to help advance relcobatinib through pivotal development and prepare Enliven for its next stage of growth."

Ms. Ball brings extensive executive leadership and financial expertise in the biotechnology industry. Her experience spans corporate strategy, financing, commercial readiness and corporate governance. She has served as Chief Executive Officer of Antiva Biosciences; Chief Executive Officer of Soteria Biotherapeutics; Senior Vice President of Corporate Strategy and Chief Financial Officer of Menlo Therapeutics; and Senior Vice President and Chief Financial Officer of Relypsa, where she helped guide the company's transition from clinical development to commercial operations. Additionally, she serves on the Board of Directors of Oruka Therapeutics, where she chairs the Audit Committee. She previously served on the boards of Atreca and Forty Seven. Ms. Ball earned a Bachelor of Science from Babson College.

Following its recent announcement of FDA alignment on the final design of ENABLE-2, Enliven remains focused on initiating the pivotal Phase 3 trial of relcobatinib (ELVN-001) in patients with previously treated chronic myeloid leukemia (CML) before year-end 2026.

About Enliven TherapeuticsEnliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision medicine approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights into clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Burlingame, California. To learn more, visit www.enliventherapeutics.com and connect with us on LinkedIn and X.

Forward-Looking Statements This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning Enliven and other matters that involve substantial risks and uncertainties. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations and financial condition, or otherwise, based on current beliefs of Enliven's management, as well as assumptions made by, and information currently available to, Enliven's management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Statements that are not historical facts are forward-looking statements. Forward-looking statements in this press release include, but are not limited to: statements regarding the potential of, and plans regarding, market opportunities, commercial readiness, potential commercialization, and expectations regarding relcobatinib (ELVN-001); statements regarding the potential differentiated attributes and therapeutic benefit of relcobatinib; the continued conduct, design and future clinical evaluation of relcobatinib, including the planned ENABLE-2 Phase 3 trial and the potential timing of initiation of ENABLE-2; expectations regarding the Company's growth, transition to late-stage development and commercialization, and the creation of long-term shareholder value; and statements by Enliven's Chief Executive Officer and a member of Enliven's Board of Directors. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various risks and uncertainties, including, without limitation the limited operating history of Enliven; relcobatinib failing to demonstrate sufficient safety, efficacy, tolerability, durability, differentiated attributes or therapeutic benefit in current or future clinical trials; delays or difficulties in recruiting, enrolling or maintaining patients in relcobatinib clinical trials; the risks of delays in completing the ongoing ENABLE trial or initiating ENABLE-2; Enliven failing to complete the ongoing ENABLE trial, to initiate ENABLE-2 or to advance relcobatinib through clinical development; regulatory authorities disagreeing with Enliven's clinical trial design, endpoints or interpretation of data, or requiring additional studies or diagnostics; developments relating to Enliven's competitors and industry which may affect the development or potential market opportunity for relcobatinib; and the potential inability of Enliven to obtain regulatory approval for, or ultimately commercialize or license, relcobatinib or other product candidates; Enliven's limited resources; Enliven's limited experience as a company in designing and conducting clinical trials; Enliven's lack of commercialization expertise; the ability to attract, hire, and retain highly skilled executive officers and employees; the ability of Enliven to protect its intellectual property and proprietary technologies; the scope of any patent protection Enliven obtains or the loss of any of Enliven's patent protection; reliance on third parties, including medical institutions, contract manufacturing organizations, contract research organizations and strategic partners; geopolitical developments, general market or macroeconomic conditions; Enliven's ability to obtain additional capital to fund Enliven's general corporate activities and to fund Enliven's research and development; and other risks and uncertainties more fully described in Enliven's filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in Enliven's Annual and Quarterly Reports on Form 10-K and Form 10-Q filed with the SEC and in Enliven's future SEC filings. Except as required by applicable law, Enliven undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.

Enliven Logo

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/enliven-therapeutics-appoints-kristine-ball-to-board-of-directors-ahead-of-planned-phase-3-trial-initiation-this-year-302909108.html

SOURCE Enliven Therapeutics, Inc.

Investors: [email protected]; Media: [email protected]

Print Page

Email Alerts

RSS Feeds

Contact Us

October 6, 2026

PDF Version

Enliven remains on track to initiate ENABLE-2 before year-end 2026

BURLINGAME, Calif., Oct. 6, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the final design of the ENABLE-2 pivotal trial, a Phase 3 trial of relcobatinib (ELVN-001) in patients with previously treated chronic myeloid leukemia (CML).

United States Adopted Names (USAN) Council has adopted relcobatinib as the nonproprietary name for ELVN-001. Relcobatinib is an investigational, potent, highly selective, potentially best-in-class small molecule kinase inhibitor designed to specifically target the BCR::ABL1 gene fusion, the oncogenic driver of CML.

"We are pleased to have reached alignment with the FDA on the design of the ENABLE-2 pivotal Phase 3 trial, providing a clear path to initiate the trial before year-end," said Helen Collins, M.D., Chief Medical Officer of Enliven. "ENABLE-2 is designed to directly compare relcobatinib to the second-generation TKIs and evaluate its potential to be the best-in-class ATP-competitive inhibitor for patients with CML. We are encouraged by the enthusiasm from physicians and the broader CML community as we prepare to initiate the trial."

ENABLE-2 Phase 3 Trial Design: A 2L+ Pivotal Trial for Patients with CMLENABLE-2 is a planned randomized 2L+ phase 3 trial expected to enroll approximately 450 adults with CML previously treated with one or more tyrosine kinase inhibitors (TKIs). Participants will be randomized 1:1 to receive either relcobatinib 80 mg once daily or an investigator-selected second-generation TKI (dasatinib, nilotinib, or bosutinib). The primary endpoint is major molecular response (MMR) at Week 24, with the key secondary endpoint of MMR at Week 96.

With approximately 450 patients, the trial is designed such that an improvement in MMR rate of at least 10 percentage points over the control arm would be sufficient to demonstrate statistical superiority. We believe this difference would represent a clinically meaningful improvement over currently available second-generation TKIs.

The Company remains on track to initiate ENABLE-2 before year-end 2026.

About Enliven Therapeutics Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision medicine approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights into clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Burlingame, California. To learn more, visit www.enliventherapeutics.com and connect with us on LinkedIn and X.

Forward-Looking Statements This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning Enliven and other matters that involve substantial risks and uncertainties. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations and financial condition, or otherwise, based on current beliefs of Enliven's management, as well as assumptions made by, and information currently available to, Enliven's management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Statements that are not historical facts are forward-looking statements. Forward-looking statements in this press release include, but are not limited to: statements regarding the potential of, and plans regarding, market opportunities, and expectations regarding relcobatinib (ELVN-001); statements regarding the potential profile, activity, selectivity, safety, tolerability, efficacy, differentiated attributes, therapeutic benefit and potential best-in-class or complementary profile of relcobatinib to allosteric inhibitors; the interpretation of data from the ongoing ENABLE trial, including MMR rate, safety and tolerability data; comparisons to historical or precedent clinical trial results; the timing, content and availability of additional clinical data and presentation materials; the continued conduct, design, objectives, endpoints, dose selection and future clinical evaluation of relcobatinib, including the planned ENABLE-2 Phase 3 trial, the statistical power, sample size assumptions and expected treatment effect sizes for ENABLE-2 and the belief that such treatment benefit would be clinically meaningful, the potential timing of initiation of ENABLE-2, the potential timing and outcome of further FDA discussions and the finalization of additional Phase 3 trial design details; and statements by Enliven's Chief Medical Officer. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various risks and uncertainties, including, without limitation the limited operating history of Enliven; the potential for interim, topline and preliminary results from Enliven's clinical trials to materially change as additional patient data become available or following more comprehensive review; the potential for results from the ongoing or any future clinical trial of relcobatinib to differ from the results of earlier trials of relcobatinib; relcobatinib failing to demonstrate sufficient safety, efficacy, tolerability, durability, differentiated attributes or therapeutic benefit in current or future clinical trials; risks associated with unexpected events during the remainder of the ENABLE trial including serious adverse events, toxicities, dose reductions, discontinuations or other undesirable side effects; delays or difficulties in recruiting, enrolling or maintaining patients in relcobatinib clinical trials; the risks of delays in completing the ongoing ENABLE trial or initiating ENABLE-2; Enliven failing to complete the ongoing ENABLE trial, to present additional data, to initiate ENABLE-2 or to advance relcobatinib through clinical development; regulatory authorities disagreeing with Enliven's clinical trial design, dose selection, endpoints or interpretation of data, or requiring additional studies or diagnostics; the risk that statistical assumptions underlying the ENABLE-2 trial design may not hold, including assumptions regarding treatment effect sizes, comparator arm performance and statistical power; lack of reliability of cross-trial comparisons because the referenced data are derived from different clinical trials at different points in time, with differences in trial design and patient populations, and results may differ in head-to-head studies; developments relating to Enliven's competitors and industry which may affect the development or potential market opportunity for relcobatinib; and the potential inability of Enliven to obtain regulatory approval for, or ultimately commercialize or license, relcobatinib or other product candidates; Enliven's limited resources; Enliven's limited experience as a company in designing and conducting clinical trials; the ability to attract, hire, and retain highly skilled executive officers and employees; the ability of Enliven to protect its intellectual property and proprietary technologies; the scope of any patent protection Enliven obtains or the loss of any of Enliven's patent protection; reliance on third parties, including medical institutions, contract manufacturing organizations, contract research organizations and strategic partners; geopolitical developments, general market or macroeconomic conditions; Enliven's ability to obtain additional capital to fund Enliven's general corporate activities and to fund Enliven's research and development; and other risks and uncertainties more fully described in Enliven's filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in Enliven's Annual and Quarterly Reports on Form 10-K and Form 10-Q filed with the SEC and in Enliven's future SEC filings. Except as required by applicable law, Enliven undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.

Enliven Logo

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/enliven-therapeutics-announces-fda-alignment-on-enable-2-phase-3-trial-design-for-relcobatinib-elvn-001-in-previously-treated-chronic-myeloid-leukemia-302900300.html

SOURCE Enliven Therapeutics, Inc.

Investors, [email protected]; Media, [email protected]

Print Page

Email Alerts

RSS Feeds

Contact Us

Prompts

Enliven Therapeutics, Inc. (ticker ELVN), listed in United States.

Company History

Date Change Detail
Feb 27, 2023 Renamed IMARA INC. → ENLIVEN THERAPEUTICS, INC.

ETFs Holding Enliven Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
CANC 2.04% 74,478 $ 4.312M Aug 31, 2026
FMED 1.35% 12,000 $ 694.68K Aug 31, 2026
MEDI 0.80% 6,976 $ 337.011K Nov 12, 2026
ESSC 0.29% 1,904 $ 104.358K Jul 31, 2026
TMED 0.20% 891 $ 45.218K Jun 30, 2026
FFSM 0.19% 52,888 $ 2.899M Jul 31, 2026
AVSC 0.16% 106,711 $ 5.082M Nov 16, 2026
VFMO 0.14% 46,776 $ 2.708M Aug 31, 2026
RESM 0.11% 80 $ 4,060.00 Jun 30, 2026
FSEG 0.06% 72 $ 3,654.00 Jun 30, 2026
FESM 0.06% 69,543 $ 3.529M Jun 30, 2026
DFAS 0.05% 348,430 $ 16.833M Nov 12, 2026
MSSM 0.01% 1,553 $ 89.903K Aug 31, 2026
DFAC 0.01% 154,020 $ 7.441M Nov 12, 2026
DCOR 0.01% 51,264 $ 2.477M Nov 12, 2026
DFAU 0.00% 10,828 $ 523.101K Nov 12, 2026
DFUS 0.00% 16,538 $ 798.951K Nov 12, 2026
DXUV 0.00% 564 $ 27.247K Nov 12, 2026
AVUS 0.00% 810 $ 38.572K Nov 16, 2026